Naftali Kaminski Back

Yale School of Medicine, USA

Dr Naftali Kaminski is the Boehringer-Ingelheim Endowed Professor of Internal Medicine and Chief of Pulmonary, Critical Care and Sleep Medicine, at Yale School of Medicine. Born and raised in Israel, Dr Kaminski received his medical degree from the Hebrew University - Hadassah Medical School in Jerusalem, Israel, completed his residency in Internal Medicine at Hadassah Mount-Scopus University Hospital in Jerusalem, and a fellowship in pulmonary medicine at Sheba Medical Center in Tel-Hashomer, Israel. He received his basic science training in Dean Sheppard's laboratory at the Lung Biology Center at UCSF and in functional genomics and microarray technology at the Functional Genomics Laboratory at Roche Bioscience, Palo-Alto. Among his key scientific achievements are: The discovery of novel molecules with significant active roles in pulmonary fibrosis, including matrix metalloproteases (MMP7, MMP19) and phosphatases (SHP2, MKP5), demonstrating that microRNAs, are differentially expressed in IPF, and that some of them (let-7, mir-29, mir-33) are mechanistically involved in lung fibrosis, the discovery that the outcome of patients with IPF can be predicted based on the expression of peripheral blood proteins and genes, a finding with practical implication because of the need for risk stratification and transplant prioritization. More recently Dr Kaminski's team identified a potential antifibrotic role for thyroid hormone mimetics through improving mitochondrial function in pulmonary fibrosis and he is actively pursuing the therapeutic implementation of this discovery. Kaminski’s team has recently been active in using single-cell profiling technologies to better understand human lung disease.  They identified conserved cellular networks in the mammalian lung; published the largest single-cell RNA sequencing (scRNAseq) atlas of the human lung with a focus on pulmonary fibrosis; defined and characterized previously unrecognized aberrant basaloid cells, and col15+ endothelial cells; and provided a detailed atlas of normal lung endothelial cells with comparison to murine and in-vitro cell populations. Kaminski authored more than 315 research papers (including in Nature Medicine, NEJM, Nature Genetics, PNAS, Science Advances, Science Translational Medicine among others), review articles and book chapters and has given numerous invited talks at national and international conferences. His lab has been consistently funded by NIH since 2003, and he has led large studies such as the NHLBI’s Lung Genomic Research Consortium, the Genomic Research in Alpha-1 Antitrypsin Deficiency and Sarcoidosis (GRADS) consortium and a Center for Advanced Diagnostics and Therapeutics (CADET II). Currently, he is the PI of the Pulmonary Fibrosis Connectome project. Kaminski is committed to data sharing and dissemination and the data portals his lab generated including the IPF cell Atlas, and the Normal Lung Endothelial Cell Atlas has been used by over 10,000 unique users from five continents and over 50 countries.  His awards include the Coalition for Pulmonary Fibrosis Marvin Schwarz Award for Pulmonary Fibrosis, the University of Pittsburgh Innovator Award, the American Thoracic Society Recognition of Scientific Achievements award, the Helmholtz Institute International Fellow Award, the European Respiratory Society Gold Medal for Interstitial Lung Disease, the Andy Tager Excellence in Mentoring Award, and the Yale Blavatnik Innovation Award. Kaminski is committed to improving the diagnosis, care, and outcomes of patients with advanced lung disease, as well as educating the next generations of researchers in clinicians and has mentored more than 40 students, fellows, and postdoctoral researchers.